Leerink Partners analyst Stephanie Davis maintained a Buy rating on Progyny (NASDAQ:PGNY) on Friday, setting a price target of $59, which is approximately 6.16% below the present share price of $62.87.
Davis expects Progyny to post earnings per share (EPS) of $0.21 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Progyny, with an average price target of $79.67.
The analysts price targets range from a high of $80 to a low of $79.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $128.65 million and a net profit of $11.66 million. The company's market cap is $5.62 billion.
According to TipRanks.com, Leerink Partners analyst Stephanie Davis is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 17.2% and a 63.09% success rate.
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.